TAK vs FATE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TAK Captures Institutional Edge (4โ0 Pillars ยท 8โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, TAK trades at 12.7x Forward P/E with 16.6% operating margin (+6.7% YoY revenue) versus FATE at N/M Forward P/E and -1495.4% operating margin (+9.2% YoY). In options structure, TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against FATE sits in BREAKDOWN (20th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TAK | FATE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $67.5B | $162.9M | Larger Scale | TAK |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | 12.7x | N/M | Lower Multiple | TAK |
| Revenue Growth (YoY) Growth | +6.7% | +9.2% | Higher Growth | FATE |
| Operating Margin (TTM) Profitability | 16.6% | -1495.4% | Higher Margin | TAK |
| Net Profit Margin Profitability | 0.9% | 0.0% | Higher Margin | TAK |
| Return on Equity (ROE) Capital Efficiency | 0.6% | -60.8% | Higher ROE | TAK |
| 52-Week Range Position Momentum | 97% ($14โ$22) | 8% ($1โ$3) | Stronger Trend | TAK |
| Beta / 30D Volatility Risk Regime | -0.02ฮฒ ยท 22% Vol | 2.16ฮฒ ยท 104% Vol | Lower Realized Risk | TAK |
| Unified Institutional Score Composite Signal | 47.7 / 100 (HOLD) | 41.9 / 100 (SELL) | Higher Composite | TAK |